Back

Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the swedish AROS study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Obesity (1) Obesity ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Viveca Ritsinger

Karolinska Institute, Stockholm (Sweden)

6 More presentations in this session

Presentation thumbnail
Associations of TyG Index and TyG-obesity-related parameters to cardiovascular disease
Associate Professor L. Bikdelu (Mashhad, IR)
Abstract Slides Video
Presentation thumbnail
Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial
Professor N. Sattar (Glasgow, GB)
Abstract Slides
Presentation thumbnail
Comprehending the genetic obesity basis could help in cardiometabolic disease prevention in women
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Prevalence, risk factors, and time-trends in abdominal obesity in 36 countries in the WHO African region from 2003 to 2022: a study of 53 WHO STEPS surveys representing 156 million adults
Doctor K. Agboyibor (Paris, FR)
Abstract Slides
Presentation thumbnail
New pediatric waist-to-height ratio adiposity cutoff predicts adulthood hypertension: analysis of 7243 participants from NHANES 2021-2023
Doctor D. Corsi (New Brunswick, US)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Presentation
Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources